Company intelligence / Profile preview

EnlitenAI

San Francisco, California, United Statesenlitenai.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EnlitenAI has developed the Neuroliten platform—a cloud-based, device-integrated AI system that aggregates real-world data from wearables and patient/caregiver input to generate actionable insights for personalized seizure treatment. The company has been recognized as a quarterfinalist at the Digital Health Awards due to its innovative approach. Early clinical use cases are being explored with academic partners such as UCSF and UCHealth, focusing on improving outcomes in epilepsy by enabling faster medication titration and more precise care plans based on continuous monitoring data.

Therapeutic areas: Neurology
Modalities: Non-pharmacological therapyDevice
Industry: Digital Health Medical Devices

Partnerships

Academic collaborations with UCSF Department of Neurology/Epilepsy Center and UCHealth clinicians.

Beyond the preview

Go deeper on EnlitenAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnlitenAI.

Explore the full profile